MedTrace Logo

A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)

NCT06811246 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-02-06

No results posted yet for this study

Summary

The goal of this study is to learn what happens to the medication islatravir (ISL), in a healthy person's body over time--called a pharmacokinetic (PK) study. Researchers want to compare the amount of islatravir in the blood when it is taken alone as a single dose and when it is taken with multiple doses of another medication called lamivudine (3TC).

Conditions

  • Healthy

Interventions

DRUG

Islatravir (ISL)

Oral administration of a single dose in period 1 and period 2

DRUG

Lamivudine (3TC)

Oral administration of multiple daily doses for 27 days

Sponsors & Collaborators

Principal Investigators

  • Medical DIrector · Merck Sharp & Dohme LLC

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-07
Primary Completion
2024-07-14
Completion
2024-07-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06811246 on ClinicalTrials.gov